SCHEMBL20239161

SCHEMBL20239161

CNS(=O)(=O)Cc1ccc(Oc2cc(CNc3ncc(C(F)F)cn3)ccn2)cc1

nearest known ligand 0.36

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
DGAT2 Q96PD7 1/20 0.36
LOXL2 Q9Y4K0 7/20 0.34
HDAC6 Q9UBN7 1/20 0.34
LOX P28300 5/20 0.34
ADORA2A P29274 1/20 0.34
ADORA2B P29275 1/20 0.34
VNN1 O95497 4/20 0.32
MET P08581 1/20 0.32
ACACB O00763 2/20 0.32
KDR P35968 1/20 0.32
MAPK14 Q16539 1/20 0.32
TNNI3K Q59H18 1/20 0.32
CLK1 P49759 1/20 0.31
CLK2 P49760 1/20 0.31
DYRK1A Q13627 1/20 0.31
CLK4 Q9HAZ1 1/20 0.31
DYRK1B Q9Y463 1/20 0.31
MMP1 P03956 1/20 0.31
MMP13 P45452 1/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20239324 0.87 VNN1 (0.41) DGAT2LOXL2LOXVNN1CLK1
SCHEMBL20239198 0.87 DGAT2 (0.37) DGAT2LOXL2LOXVNN1CLK1
SCHEMBL20239285 0.86 VNN1 (0.38) DGAT2LOXL2HDAC6VNN1MET
SCHEMBL20239299 0.78 LOXL2 (0.57) LOXL2LOX
SCHEMBL20239265 0.77 DGAT2 (0.42) DGAT2LOXL2HDAC6LOXVNN1
SCHEMBL20239314 0.76 DGAT2 (0.48) DGAT2LOXL2LOXVNN1MET
SCHEMBL20239230 0.76 DGAT2 (0.47) DGAT2LOXL2LOXVNN1CLK1
SCHEMBL20239332 0.75 MET (0.38) DGAT2HDAC6VNN1METKDR
SCHEMBL18249759 0.73 DGAT2 (0.49) DGAT2VNN1CLK1CLK2DYRK1A
SCHEMBL20239261 0.72 DGAT2 (0.51) DGAT2VNN1METKDRCLK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3298001-B1 DGAT2 INHIBITORS LILLY CO ELI (US) 2020-05-13 EP disclosed
US-10053429-B2 DGAT2 inhibitors ELI LILLY AND COMPANY (US) 2018-08-21 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed
US-20180162825-A1 NOVEL DGAT2 INHIBITORS ELI LILY AND COMPANY (US) 2018-06-14 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180162825-A1 NOVEL DGAT2 INHIBITORS DGAT2, DGAT1, LCAT DGAT2 1/4885LOXL2 2081/4885HDAC6 1251/4885
US-10053429-B2 DGAT2 inhibitors DGAT2, DGAT1, LCAT DGAT2 1/4885LOXL2 1951/4885HDAC6 1230/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.